Investing in health is the “long-termism” that entrepreneurs should adhere to.

For a long time, my country’s nutritional supplement market has been full of various noises. Arguments such as “IQ tax” have never stopped. But on the other hand, as the “fourth meal economy” that caters to all ages, the faster aging of the population and the rise of the punk health trend of “soaking wolfberries in thermos cups” among young people have led to a clear growth trend in the industry. At the same time, the increase in people’s health awareness has also promoted the improvement of the industry chain, making the field of nutritional supplements more diverse, more refined and more daily.

Swisse and its parent company, Biostime Group, have seized this trend and filled the gap in the domestic mid-to-high-end nutritional products market with the Swisse PLUS series. While practicing the brand concept of PPA (Premium, Proven, Aspirational), they have continued to increase investment in scientific research.

In 2021, H&H Group officially established the global R&D organization, the H&H Scientific Committee, which together with the research and innovation centers in China and Ireland, the translational science teams in Australia and Switzerland, and the regional product development centers in China, Australia, France and the United States, formed a strong global R&D network. At the same time, H&H Group also cooperates with authoritative institutions, universities and organizations around the world to promote the integration of industry, academia and research, and accelerate the implementation and transformation of R&D results in different fields. 

Recently, Biostime Group released its 2022 Sustainability Report. Over the past year, the group has invested more than US$23.5 million in research and development, carried out 29 scientific projects, added 21 new patents, and launched 247 new products in the global market.

While increasing investment, the long-term strategy has also reaped rich rewards. According to the latest financial report released by Biostime Group, as of December 31, 2022, the group’s revenue was 12.78 billion yuan, a reported growth of 10.6%. Revenue in the Chinese market increased by 6.4% year-on-year, and the group’s total cash balance was 2.3 billion yuan. In addition, Swisse is currently ranked first among participants in the online vitamin, herbal and mineral supplement market in mainland China.

In the post-epidemic era, people’s Maslow needs are constantly moving upward, from “living for others” to “pleasing oneself”, and the nutritional products market still has great potential. In this context, based on the needs of population segmentation, Swisse PLUS brings consumers a new “solution” for healthy living. It is another representative of the industry’s long-termism and a worthy health partner.